Updated version at IIIT Delhi


Gajendra P.S. Raghava
Chief Scientist & Head Bioinformatics Centre
Institute of Microbial Technology
Chandigarh, India

Background: Raghava is a scientist working at Bioinformatics Centre, Institute of Microbial Technology (IMTECH), Chandigarh, India. He did his MSc Physics from N.A.S. College, Meerut, UP in 1984; and MTech from Indian Institute of Technology (I.I.T.), New Delhi in 1986. In 1996 he received a doctorate in bioinformatics from Institute of Microbial Technology and Panjab University, Chandigarh.

Professional Experience: He worked as Postdoctoral fellow at Oxford university, Oxford and European Bioinformatics Institute, Cambridge UK (1996-98). Worked as Bioinformatics specialist at UAMS, USA (2002-3 & 2006) where he establish bioinformatics infastructure. Raghava woked as visiting professor at POSTECH, South Korea (2005)

Scientific Contribution: Raghava is a strong suporter of open source software and open access, all resouces develoed at his group are free for scientific use. His group developed more than 200 web servers and 30 databases in the field of computer-aided drug/vaccine design (probably highest number of services developed/maintained from a single group in the world). These services are heavily used by scientific community, nearly 125,000 hits per day. Group published more than 200 research papers in reputed journals with avargae impact factor around 4.0 Most of papers are highly cited, total citations more than 8300 with h-index 48 and g-index 131 as per google scholar. In addition group contributed/maintained number of web sites that include i) CRDD, ii) OSCADD, iii) OSDDlinux, iv) CSIR Informatics Portal, v) GENESIS, vi) GPSR Packages, vii) OSDDchem, viii) Sysborg2, ix) OSDD .

Major Awards/Honours: He got following major national awards/recognition

Latest News

EbolaVCR: Computational resources for designing therapeutics against Ebola Virus

MtbVeb: Designing Vaccines against Existing and Emerging Strains of Mycobacterium tuberculosis

CancerDP: Prioritization of anticancer drugs based on genomic features...